Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical Trial
Mehdi Hamadani(Medical College of Wisconsin), Susan O'Brien(University of California, Irvine Medical Center), Gary Simmons(Virginia Commonwealth University Medical Center), Pingping Mao, Fevzi Yalniz, Tatyana Feldman(Hackensack University Medical Center), Mara Bryan(Caribou Biosciences (United States)), Elizabeth Brém(UC Irvine Health), Enrique Zudaire(Centro de Investigación del Cáncer), Eric Stawiski(Caribou Biosciences (United States)), David Lavie(Hadassah Medical Center), Paul D. Donohoue(Caribou Biosciences (United States)), Tina Albertson(Seagen (United States)), Boyu Hu(University of Utah), Erin Mullane(University of Washington), Mohamad Cherry(University of Oklahoma Health Sciences Center), Don A. Stevens(Norton Healthcare), Ine-Mari Bornman(Caribou Biosciences (United States)), Tonia Nesheiwat, James Essell(Oncology Hematology Care), Shally Chung(Caribou Biosciences (United States)), Elizabeth Garner(Caribou Biosciences (United States)), Abraham S. Kanate(HonorHealth), Lindsay McFarland(Caribou Biosciences (United States)), Costas K. Yannakou(Epworth Hospital), Maria do Socorro Oliveira Portella(Hospital Alemão Oswaldo Cruz), B. Carnley(Royal Perth Hospital), Kenneth Micklethwaite(Westmead Hospital), Donna Marcy(Caribou Biosciences (United States)), Houston Holmes(Texas Oncology), Chris Holland(Amgen (United States)), Rushang D. Patel(AdventHealth Orlando), Ayad Hamdan(University of California San Diego), Elaine Alambra(Caribou Biosciences (United States)), Tom Kochy(Caribou Biosciences (United States)), Vamsi Kota(Augusta University Health), Umar Farooq(University of Iowa Hospitals and Clinics), Sunita Nasta(University of Pennsylvania), Govind Shah(Caribou Biosciences (United States)), Loretta J. Nastoupil(Sisters of Mercy Health System), Melhem M Solh(Northside Hospital), Stephen J. Schuster(University of Pennsylvania), Jim Peck(Caribou Biosciences (United States)), Karen Lyle(Caribou Biosciences (United States)), Justin Skoble(Caribou Biosciences (United States)), Muhammad Husnain(University of Arizona), Cesar Gentille Sanchez(Winthrop Rockefeller Foundation), Ashraf Garrett
Cited by 0
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869